CHARLOTTE, North Carolina (GenomeWeb) – Roche this week previewed its new set of sequencing-based liquid biopsy assays for cancer research, hosting an early-access tester of the products who shared some of her data at the Association for Molecular Pathology meeting held here.
Shelly Gunn, chief medical officer of contract diagnostics organization ResearchDx (and medical director of its subsidiary Pacific Diagnostics Clinical Laboratory) introduced the new assays, which Roche has named "Avenio ctDNA kits," at a workshop on Wednesday.